Instil Bio, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.2M | $2.2M | $2.2M | $2.2M | $2.2M | $2.8M | $1.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $5.1M | $5.3M | $6.1M | $5.9M | $6.2M | $9.1M | $10.4M | $10.7M |
| Operating Income | $-5.6M | $-7.0M | $-9.6M | $-15.0M | $-23.4M | $-30.6M | $-11.8M | $-23.6M |
| Operating Margin | -248.9% | -312.7% | -426.3% | -670.0% | -1,045.5% | -1,363.2% | -426.1% | -1,582.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-4.3M | $-4.2M | $-8.2M | $-13.6M | $-21.4M | $-28.2M | $-11.9M | $-23.0M |
| Net Margin | -191.7% | -187.5% | -365.3% | -606.0% | -954.2% | -1,257.8% | -428.8% | -1,541.9% |
| EPS (Basic) | $-0.63 | $-0.62 | $-1.13 | $-2.01 | $-3.24 | $-4.32 | $-1.82 | $-3.54 |
| EPS (Diluted) | $-0.63 | $-0.62 | $-1.13 | $-2.01 | $-3.24 | $-4.32 | $-1.82 | $-3.54 |
| Shares Outstanding (Basic) | 6.8M | 6.8M | 6.7M | 6.8M | 6.6M | 6.5M | 6.5M | 6.5M |
| Shares Outstanding (Diluted) | 6.8M | 6.8M | 6.7M | 6.8M | 6.6M | 6.5M | 6.5M | 6.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |